Molekule Consulting Inc. today announces its exhibiting at the 2015 Pharma Competitive Intelligence Conference & Exhibition USA

Monday, May 4 2015 – 11:00am EDT Miami, FL, USA

Molekule Consulting, Inc. is recognized as a global leader in the development and refinement of primary competitive insights and intelligence for the biopharmaceutical and life sciences industries. Molekule aligns intelligence outcomes, focuses results and enables its client partners the ability to "win" in a highly dynamic and competitive biopharmaceutical vertical. We remain trusted partners of biopharmaceutical players today and tomorrow.

At the Pharma CI USA Conference, Mr. Alderman will present a talk entitled, "CI=ROI. Emerging Markets in biopharmaceuticals – how leveraging primary competitive intelligence returns robust ROIs in key global growth driver markets" where he will discuss emerging markets as targets and subjects of competitive intelligence research. On a global scope and scale, biopharmaceutical companies are keen to seek novel avenues of overt growth and sustainable profitability. Emerging markets & Tier 2 and 3 markets in the pharmaceutical and biotech sectors are critical to many MNC and super-regional players' fundamental corporate-level strategies. As such, the delivery of accurate and actionable primary competitive insights and intelligence in these "untraditional" markets is key to long-term sustainable success. In this talk, David Alderman, President of Molekule Consulting, will describe the competitive factors impacting pharmaceutical emerging markets and detail how the power of competitive intelligence enables biopharmaceutical executives to measurably surpass the competition.

"The Pharma CI Conference USA is the forum in biopharmaceutical competitive intelligence to 'see and be seen,'" said David L. Alderman, President of Molekule Consulting Inc.

"As a firm, Molekule continues to grow our global footprint and putting the Molekule Consulting brand at the forefront of Pharma CI USA as a medal-level sponsor is something we believe is critical to educating biopharmaceutical CI consumers and clients of the differentiation and benefits of the Molekule brand," stated Alderman.

"Pharma today in 2015 is vastly different than fifteen [15] years ago; highly active genericization, biosimilars and widespread globalization confer significant impact and implication on everyday operations and ultimately are translated to the bottom line. Molekule Consulting's clients want to know more than simply a data dump of key intelligence findings; rather, they are keen to understand a high degree of contextualization and an overall actionability and implication associated with competitor and market intelligence. Novel or untraditional channels of revenue generation that may offset peri-LoE/post-LoE or emerging ethical in-market threats is highly sought after. The BRIC-MT and Tier 2/Tier 3 markets are one of these avenues by which biopharmaceutical players can materially impact bottom-line growth and drive new revenue streams. However, going in 'blind' is not advisable – there are numerous local players and per market cultures/differences that need to be understood, as well as other competitor MNCs' plays into those markets. Thus the need for granular, accurate and actionable primary competitive intelligence and insights," said Alderman.

About Molekule Consulting Inc.

Molekule Consulting Inc. ("Molekule") is a recognized global leader in the development and refinement of primary competitive insights and intelligence for the biopharmaceutical and life sciences industries. Molekule aligns intelligence outcomes, focuses results and enables our client partners the ability to "win" in the highly dynamic and competitive biopharmaceutical space. Molekule Consulting remains a trusted partner of biopharmaceutical players today and tomorrow.

More information about Molekule Consulting, Inc. can be found at:
www.molekuleconsulting.com

Contact:
Molekule Consulting Inc.

Corporate:
David Alderman, President, +1 305-504-3030; [email protected]

 

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.